Desjardins Insurance
Life • Health • Retirement

C. P. 3950
Lévis (Québec) G6V 8C6
desjardinslifeinsurance.com/planmember
1-844-410-6485

PRIOR AUTHORIZATION REQUEST
LYNPARZA (OLAPARIB)
ZEJULA (NIRAPARIB)

PLEASE READ THE INSTRUCTIONS ON THE LAST PAGE OF THIS FORM.

A PATIENT IDENTIFICATION – To be completed by the member.

Patient's last and first name | Relationship with member: ☐ Member ☐ Spouse ☐ Dependent child | Patient's date of birth (YYYY MM DD)

Member's last and first name | Contract No. | Certificate No.

No., street, apt. | City | Province | Postal code

Telephone Nos – Home: | Office: | Extension: | Email:

Since the response to this request includes confidential information, please indicate how you would like to be informed of the decision:

☐ By mail (The response to your request will be sent to the address indicated in this section.) ☐ By fax:

Coordination of benefits: If the patient has coverage under a private insurance plan or is enrolled in a provincial drug insurance plan, please submit the request to this plan first. Then send us a copy of the decision notice and this form filled out by the physician, so we can analyze the request.

PRIVATE PLAN

Does the patient have drug coverage under a private insurance plan?

☐ **Yes** – Please provide a copy of the notice of approval or refusal. → ☐ **Copy attached to this form.**

Specify: Name of the insurer: _____ Contract No.: _____ Certificate No.: _____

☐ **No**

PROVINCIAL PLAN

Has a request for reimbursement been submitted under your provincial plan?

☐ **Yes** – Please provide a copy of the notice of approval or refusal. → ☐ **Copy attached to this form.**

☐ **No** – Please explain:

PATIENT SUPPORT PROGRAM

Is the patient enrolled in a patient support program? ☐ **Yes** ☐ **No**

If so – Program name: _____

Contact person: | Telephone No.: | Extension:

B1 DECLARATION AND AUTHORIZATION FOR THE COLLECTION AND COMMUNICATION OF PERSONAL INFORMATION

All the information I have provided on the claim form is accurate and complete. I authorize Desjardins Financial Security Life Assurance Company, hereinafter Desjardins Insurance, strictly for the purposes of managing my file and settling this claim to: (a) collect from any person or legal entity, or from any public or parapublic organization, only the information deemed necessary to manage my file. The non-exhaustive list of sources from which information may be collected includes healthcare professionals or facilities, and insurance companies; (b) communicate to the said persons or organizations only the personal information about me that is deemed necessary for the purposes of my file; (c) when necessary use the personal information it may have about me in existing files that are now closed. This authorization is also valid for the collection, use and communication of personal information concerning my dependents, insofar as applicable to the claim. A photocopy of this authorization is as valid as the original.

Signature of member: _____ **Date:** _____

Last name and first name of parent/legal guardian (if applicable): _____

Signature of patient or parent/legal guardian (if applicable): **Date:**

B2 CONSENT TO THE COMMUNICATION OF PERSONAL INFORMATION TO A THIRD PARTY

To help us process your claim more efficiently, do you authorize Desjardins Insurance to inform the patient support program and the attending physician or the attending physician's medical team of the reasons for the decision on your prior authorization request?

☐ Yes ☐ No

Signature of member: _____ **Date:** _____

Last name and first name of parent/legal guardian (if applicable): _____

Signature of patient or parent/legal guardian (if applicable): **Date:**

C ATTENDING PHYSICIAN SECTION – To be completed by the attending physician.

Physician's last and first name (PLEASE PRINT) | License No. | Specialty

No., street, suite | City | Province | Postal code

Telephone No.: | Fax No.:

Signature of physician: **Date:**

Drug name	Formulation	Strength	Dosage	Scheduled duration of treatment

Where is the drug administered? ☐ Home ☐ Physician's office ☐ Private clinic ☐ Hospital – Inpatient ☐ Hospital – Outpatient ☐ Other (please specify):

PRINT NEW REQUEST

C ATTENDING PHYSICIAN SECTION – Continued

- **Make sure to fill out all sections so we can process the request faster. If any information is missing, we will send the form back to the member.**
- **In order to consider any diagnosis not mentioned on this form, we need supporting documents (clinical practice guidelines, clinical studies, etc.) that justify the drug's use in the given context.**

DIAGNOSIS

☐ Epithelial ovarian, fallopian tube or primary peritoneal cancer

☐ Metastatic castration-resistant prostate cancer

☐ Early stage breast cancer, adjuvant treatment

☐ Other therapeutic indication(s) – Please specify:

INFORMATION RELATING TO EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Was the disease diagnosed according to the Health Canada approved indications? ☐ Yes ☐ No

Please indicate if patient presents a mutation on BRCA1 or BRCA2 gene: ☐ Yes ☐ No

If no, please specify: _____

Will the treatment be administered as monotherapy? ☐ Yes ☐ No

ECOG performance status: _____

Is the cancer high grade? ☐ Yes ☐ No

FIGO stage: ☐ I ☐ II ☐ III ☐ IV

INFORMATION RELATING TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Please indicate if patient has a germinal or somatic BRCA gene mutation: ☐ Germinal ☐ Somatic

Has the disease progressed during or following a treatment with an androgen synthesis inhibitor or a second-generation androgen receptor inhibitor? ☐ Yes ☐ No

Will the treatment be administered in association? ☐ Yes, please specify: _____ ☐ No

Is chemotherapy clinically indicated? ☐ Yes ☐ No, please explain: _____

ECOG performance status: _____

INFORMATION RELATING TO EARLY STAGE BREAST CANCER, ADJUVANT TREATMENT

Will the treatment be administered as monotherapy? ☐ Yes ☐ No

Is the tumor : ☐ Oestrogen receptor positive ☐ Progesterone receptor positive ☐ None

Does the tumor overexpress HER2 receptor? ☐ Yes ☐ No ☐ Low over expression (meant by low over expression an immunohistochemistry (IHC) score of 1+ or a IHC score of 2+ with a negative In situ hybridization(ISH) result)

Has the tumor been completely resected? ☐ Yes, resection date: _____ ☐ No

Indicate if the patient has a germinal BRCA gene mutation: ☐ Yes ☐ No

Has the patient already been treated by a PARP inhibitor? ☐ No ☐ Yes, please specify the indication and the reason why the treatment was stopped: _____

Define the high risk of recurrence by checking the situations that apply to the patient:

☐ Absence of a complete pathological response following neoadjuvant chemotherapy
☐ Absence of a complete pathological response and a CPS-EG score ≥3 following neoadjuvant chemotherapy
☐ Pathological stage ≥pN1 or ≥pT2 prior to the initiation of adjuvant chemotherapy
☐ Pathological involvement of ≥4 lymph nodes prior to the initiation of adjuvant chemotherapy
☐ None of the above, explain: _____

ECOG performance status: _____

PRIOR MEDICATION OR TREATMENT

Has the patient ever used medication or received treatment for this medical condition? ☐ Yes ☐ No

If not, please explain: _____

If so, please list any medication already used or any treatment already received for this medical condition*:

*** If the patient has received platinum-based chemotherapy, please specify drug and dates of treatment.**

Medication or treatment name	Dose	Start of treatment	End of treatment	Number of cycles	Reaction to treatment

The patient is in response (complete or partial) to platinum-base chemotherapy: ☐ Yes ☐ No

C ATTENDING PHYSICIAN SECTION – Continued

PRESCRIPTION RENEWAL

Is there a complete response* to treatment? ☐ Yes ☐ No

** A complete response means the absence of all clinical and radiologic signs of the disease, accompanied by normal CA-25 levels.*

Please provide objective data that shows a satisfactory clinical or biological response: _____

_____

_____

D INSTRUCTIONS – HOW TO COMPLETE AND RETURN THIS FORM

1. Complete sections A and B.
2. Ask your physician to complete section C. The member is responsible for assuming any costs incurred to complete this form or to obtain additional information.
3. To obtain a reimbursement once the drug has been approved, please use your payment card at the pharmacy or submit your original receipts by mail. Eligible drugs must be dispensed by a pharmacist or a physician, if there is no pharmacist.
4. Send form:

by fax: Desjardins Insurance
Group Insurance, Health Claims,
418-838-2134 or 1-877-838-2134 (toll-free)

by mail: Desjardins Insurance
Group Insurance, Health Claims
C. P. 3950, Lévis (Québec) G6V 8C6

Under its prior authorization program, Desjardins Insurance authorizes the reimbursement of certain drugs that meet criteria that are based, in particular, on clinical practice guidelines and recommendations issued by health technology assessment organizations. The drug will be eligible for reimbursement if it meets the insurer's criteria, if it's not administered in a hospital and if it's not eligible under a government program. If the information on your form is complete, your request will normally be processed within 5 business days.

When the request form is received, it will be assessed in the strictest confidence. In some situations, additional diagnostic or clinical information may be required.

If the treatment continues beyond the authorized period, you will be asked to submit a new request form and provide information that justifies the extension of treatment. If you have a payment card, your pharmacist will be advised that the authorization period is coming to an end. The insurance must be in force and the patient still covered on the date expenses are incurred. This prior authorization is subject to change if, at the time expenses are incurred, the contract has been modified.

When Desjardins Insurance declines a prior authorization request, it is because we need to uphold conditions set out in the contract. It does not mean we are questioning the physician's opinion. If you have any questions, please contact our Customer Contact Centre at the number indicated on page 1 of this form.